Cipla grants global commercialization rights for nasal spray ‘Dymista’ to Meda

06 Jun 2013 Evaluate

Cipla has granted the global commercialization rights for its nasal spray ‘Dymista’ to Swedish partner Meda AB except for certain geographies. The two companies have extended an existing partnership for development under which Meda will have full coverage in all growth markets in Latin and South America, West Asia and Africa and Asia, including more than 120 new markets for the nasal spray prescribed for allergic rhinitis.

Under their extended agreement, both partners will collaborate on follow-up compounds for Dymista, capitalizing on intellectual property retained by both partners. Cipla will be responsible for formulation, while Meda will be responsible for clinical development, registration, marketing and sales. The companies will also collaborate on future production of Dymista and any new products developed.

Dymista is a novel nasal treatment of allergic rhinitis. Dymista was approved in the US in May 2012 and in Europe in January 2013.

Cipla Share Price

1502.65 -4.60 (-0.31%)
16-Dec-2025 10:38 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1783.25
Dr. Reddys Lab 1274.40
Cipla 1502.65
Zydus Lifesciences 920.80
Lupin 2083.45
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×